10-Q: Earth Science Tech Reports Strong Q1 2025 Results Driven by Pharmaceutical Sales

Earth Science Tech, Inc. reports a significant increase in revenue and a shift to profitability in the first quarter of fiscal year 2025, primarily driven by its pharmaceutical and telemedicine subsidiaries.

Summary

• Earth Science Tech, Inc. reported a net income of $1,076,254 for the quarter ended June 30, 2024, a significant turnaround from a loss of $35,596 in the same period last year.
• The company's revenue surged to $8,568,918, compared to $219,934 in the prior year, primarily due to the acquisition of RxCompound and Peaks.
• Gross profit for the quarter was $6,410,434, representing a gross margin of 75%, compared to a gross profit of $148,769 and a 68% margin in the same quarter of the previous year.
• Operating expenses totaled $5,345,416, a substantial increase from $171,747 in the prior year, driven by increased labor and professional fees.
• The company's cash balance increased to $1,384,407 from $697,721 at the end of the previous quarter.
• The company repurchased 914,108 shares of its common stock for $158,473.39 during the quarter.

Sentiment

Score: 8

Explanation: The document shows a strong positive shift in financial performance with significant revenue growth and a move to profitability. However, there are some concerns about increasing operating expenses and reliance on a few key customers and suppliers.

Positives

• The company has achieved a significant turnaround in profitability, moving from a loss to a substantial net income.
• The company has experienced a massive increase in revenue, primarily due to the acquisition of RxCompound and Peaks.
• The company has improved its gross profit margin, indicating better cost management and pricing strategies.
• The company has significantly increased its cash balance, providing more financial flexibility.
• The company has reduced its long-term debt, leading to lower interest expenses.
• The company has successfully repurchased shares, potentially increasing shareholder value.

Negatives

• Operating expenses have increased significantly, primarily due to higher labor and professional fees.
• The company's accrued expenses have increased substantially, mainly due to officer compensation.
• The company has a concentration of revenue with three large customers accounting for 11%, 9% and 8% of revenue respectively.
• The company has a concentration of suppliers with three main suppliers accounting for 29%, 14% and 4% of vendor purchases respectively.

Risks

• The company's reliance on a few large customers could pose a risk if any of these customers reduce their purchases.
• The company's dependence on a limited number of suppliers could create supply chain vulnerabilities.
• The significant increase in operating expenses, particularly labor and professional fees, could impact future profitability if not managed effectively.
• The company's accrued expenses, especially officer compensation, could raise concerns about financial management.
• The company's cash balance exceeds federally insured limits, which could pose a risk if the financial institution fails.

Future Outlook

The company intends to expand its offerings to include over-the-counter (OTC) products such as supplements and topicals. The company also plans to expand its prescription fulfillment capabilities as RxCompound obtains licenses in additional states.

Management Comments

• Management believes that the increase in revenue is primarily due to the acquisition of RxCompound and Peaks.
• Management states that the company is focused on the health and wellness industry.
• Management believes that the company's internal controls over financial reporting were reasonably effective as of the Evaluation Date.

Industry Context

The company's focus on compounding pharmaceuticals and telemedicine aligns with the growing trend of personalized medicine and remote healthcare services. The company's expansion into OTC products also reflects the increasing consumer interest in self-care and wellness.

Comparison to Industry Standards

• The company's revenue growth significantly exceeds the average growth rate for the pharmaceutical and telemedicine industries, which typically see single-digit or low double-digit growth.
• The company's gross profit margin of 75% is higher than the industry average, which is typically between 50% and 70% for pharmaceutical companies.
• The company's shift to profitability is a positive sign, as many early-stage companies in the healthcare sector struggle to achieve profitability.
• Compared to companies like Teladoc Health and GoodRx, which are major players in the telemedicine and online pharmacy space, Earth Science Tech is still a smaller company but is showing strong growth potential.
• The company's focus on compounding pharmaceuticals is a niche market that allows it to offer customized medications, which differentiates it from larger pharmaceutical companies that focus on mass-produced drugs.

Related Party Transactions

• The company pays employee compensation to Giorgio R. Saumat and Mario Tabraue through their respective LLCs.
• The company repurchased shares through Avenvi, LLC, owned by Giorgio R. Saumat, to avoid higher fees from third-party firms.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and stock repurchase program.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a wider range of products and services as the company expands its offerings.
• Suppliers may benefit from increased orders as the company grows.

Next Steps

• The company plans to expand its offerings to include over-the-counter (OTC) products.
• The company plans to expand its prescription fulfillment capabilities as RxCompound obtains licenses in additional states.
• The company will continue to evaluate and improve its internal controls over financial reporting.

Key Dates

Keywords

pharmaceuticals, telemedicine, compounding pharmacy, revenue growth, profitability, financial results, healthcare, RxCompound, Peaks, stock repurchase